Table 2.
Baseline characteristics of included patients for the intention-to-treat analysis (n = 781)
| Characteristic | Control strategy (n = 292) | Intervention strategy (n = 489) | P value |
|---|---|---|---|
| Mean age (SD, range), years | 67 (9.9, 28–92) | 67 (9.9, 26–95) | 0.55e |
| Male | 171 (59%) | 265 (54%) | 0.23f |
| Pathology after resection | 0.64g | ||
| CRC | 284 (97%) | 473 (97%) | |
| No CRC | 6a (2.1%) | 14b (2.9%) | |
| No pathology, clinically CRC | 2 (0.7%) | 2 (0.4%) | |
| CRC locationc,d | 0.64g | ||
| Left | 182 (64%) | 315 (66%) | |
| Right | 103 (36%) | 154 (32%) | |
| Both | 1 (0.3%) | 6 (1.3%) | |
| CRC patternc | 0.06g | ||
| First CRC | 268 (94%) | 450 (95%) | |
| Synchronous CRC | 5 (1.7%) | 16 (3.4%) | |
| Local recurrence | 7 (2.4%) | 7 (1.5%) | |
| Metachronous CRC | 6 (2.1%) | 2 (0.4%) | |
| Family history reported at intake | 179 (61%) | 364 (74%) | 0.000f |
| FCC/hereditary CRC syndrome at intake | |||
| Yes | 7 (2.4%) | 9 (1.8%) | 0.61f |
| Lynch syndrome | 0 | 0 | |
| Lynch syndrome ruled out | 1 | 3 | |
| Familial colorectal cancer | 0 | 0 | |
| Serrated polyposis syndrome | 1 | 2 | |
| Adenomatous polyposis (FAP, MAP, non-genetic) | 2 | 3 | |
| Syndrome unknown | 3 | 1 | |
| Second opinion/referral | 31 (11%) | 34 (7.0%) | 0.07f |
aFive benign lesions and one patient with an ovarian carcinoma
bAll benign lesions
cNon-CRC lesions not included
dRight or left from splenic flexure
e2-Sided unpaired t-test
f2-Sided chi square test
gFisher’s exact test